Home > Boards > US OTC > Medical - Healthcare >

GT Biopharma Inc. (GTBP)

Add GTBP Price Alert      Hide Sticky   Hide Intro
Moderator: CashBowski
Search This Board: 
Last Post: 1/16/2018 5:51:11 PM - Followers: 167 - Board type: Free - Posts Today: 0


Oxis International Inc.

Below shows OXS-1550 WORKING - Soon to enter Phase II with FDA!


Treating Non-Hodgkin's lymphoma

OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.

Treating triple-negative breast cancer

Our lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

Treating multiple myeloma

Our lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.



Company Website


Corporate Overview - Presentation
Fall 2015
Click the link:





OXIS Conference Call  March 31, 2015

CEO Interview with The Wolf of Weedstreet




Sean Xie, MD, PhD, EMBA is a tenured Professor at the Department of Pharmaceutical Sciences/Drug Discovery Institute at University of Pittsburgh and Associate Dean for Research Innovation at the School of Pharmacy. He is Principal Investigator of an integrated research laboratory of CompuGroup, BioGroup and ChemGroup, and Founding Director of Computational Chemical Genomics Screening Center. Dr. Xie is also Director/PI of NIH funded National Center of Excellence for Computational Drug Abuse Research. Dr. Xie holds joint faculty positions at the Departments of Computational System Biology and Structural Biology, and Pittsburgh Cancer Institute MT/DD Program. He serves as an invited guest editor for AAPS Journal, Editorial Board of American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology and Toxicology. In 2013, he was named an honorary professor of Chinese Academy of Medical Sciences & Peking Union Medical College. Dr. Xie is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.


Dr. James J. Mule, Ph.D. serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center. He then moved to Palo Alto, Calif., where he was involved in the birth of two startup companies while an adjunct faculty member in the Department of Surgery, Stanford University. He moved to Ann Arbor, Mich., as the Director of the Tumor Immunology and Immunotherapy Clinical Research Programat the University of Michigan Comprehensive Cancer Center. Dr. Mule is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. The work in these areas has helped to develop new treatments for advanced cancer patients. Dr. Mule serves on the Advisory Boards of seven NCI-designated Cancer Centers and was a member of the NCI’s Board of Scientific and Clinical Counselors. He serves as Chair of the Cellular, Tissue and Gene Therapy Advisory Committee of CBER, FDA, is a Special Government Employee of the NCI and the FDA. Dr. Mule is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors.


Dr. Stephen M. Chang is Vice President-Research & Development at New York Stem Cell Foundation, Chief Scientific Officer at Stemgent, Inc., and Independent Director at MultiCell Technologies, Inc. He is on the Board of Directors at MultiCell Technologies, Inc. Dr. Chang was previously employed as Chief Scientific Officer & Vice President by Canji, Inc., Chief Scientific Officer & Vice President by Schering-Plough Research Institute, and President & Chief Executive Officer by MultiCell Immunotherapeutics, Inc. He also served on the board at Histogen, Inc. He received his undergraduate degree from the University of Michigan and a doctorate degree from the University of California, Irvine.


Dr. Haile has special technical experience in molecular biology, immunology, plant biotechnology, including transgenic plants, cell biology, diagnostics, therapeutics, theranostics, virology, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management. Dr. Lisa Haile concentrates on patent protection.


Information on Multiple Myeloma & Cannabidiol (CBD)

After studying the effects of cannabidiol on multiple myeloma cells, researchers found that; “CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF-κB pathways with major effects in TRPV2+ cells.”

They conclude that; “These data provide a rationale for using CBD to increase the activity of proteasome inhibitors in MM.”

The study, which validates a recent National Institute of Health study which also found that cannabidiol can inhibit cancer cells, was conducted by researchers at the School of Pharmacy at the University of Camerino in Italy.


Stock Information:

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GTBP News: Current Report Filing (8-k) 01/16/2018 08:02:59 AM
GTBP News: GT Biopharma, Inc. Files Application for NASDAQ Capital Market Listing 12/18/2017 09:47:02 AM
GTBP News: Statement of Ownership (sc 13g) 12/04/2017 06:02:31 AM
GTBP News: Initial Statement of Beneficial Ownership (3) 12/01/2017 05:36:21 PM
GTBP News: Initial Statement of Beneficial Ownership (3) 12/01/2017 05:26:51 PM
#9588  Sticky Note The topic of this board is OXIS. The CashBowski 03/31/17 11:03:34 AM
#11399   I've seen GTBP promotions on Facebook also. Maybe simon wagstaff 01/16/18 05:51:11 PM
#11398   What happened to OXS-1550? simon wagstaff 01/16/18 02:01:32 AM
#11397   I just checked and they've been on promotion CashBowski 01/14/18 08:03:36 AM
#11396   Clearly pump and dump. simon wagstaff 01/10/18 03:43:06 PM
#11395   Are they still buying promo's? I haven't checked CashBowski 01/10/18 11:01:44 AM
#11394   Where are you finding shares to borrow? Oharper 01/10/18 09:23:58 AM
#11393   Good time to sell, then, if you own simon wagstaff 01/09/18 07:16:39 PM
#11392   Idc whats going on if the stock is Oharper 01/09/18 02:58:38 PM
#11391   Pump. And dump simon wagstaff 01/09/18 02:56:55 PM
#11390   Up almost 20% today, nice momo today Oharper 01/09/18 10:30:10 AM
#11389   Whooo this is huge !!!!! Let's see a simmons420 01/09/18 09:23:52 AM
#11388   GTBP Announces Completion of Dosing in Phase 1 Oharper 01/09/18 08:55:54 AM
#11387   GTBP nice volume in there today. Been holding TheOtcStockGuy 01/08/18 12:41:34 PM
#11386   The most overvalued stock in the entire OTC munimi 01/04/18 06:09:38 PM
#11385   Now is the time that this will start Prof Chaos 01/04/18 12:20:54 PM
#11384   Correct. simon wagstaff 12/27/17 12:44:03 PM
#11383   This thing is dead. Won't get up capttom1 12/27/17 11:03:57 AM
#11382   Pump squad returns. simon wagstaff 12/26/17 09:15:34 PM
#11381   I am pretty sure the NASDAQ is not scoot27 12/26/17 04:26:51 PM
#11380   I agree. Not to mention, even if billymack 12/26/17 03:11:35 PM
#11379   100% runner if they up list. The risk simmons420 12/26/17 03:09:29 PM
#11378   I agree... if GTBP manages to uplist there Suarezzz1111 12/26/17 03:08:59 PM
#11377   I can't wait to see them uplist...easy runner billymack 12/26/17 03:06:37 PM
#11376   Hi some info this used to be oxis simmons420 12/26/17 02:56:19 PM
#11375   Anyone have any info on this dog? capttom1 12/26/17 01:18:51 PM
#11374   Some seemed to think all GTBP needed to simon wagstaff 12/19/17 10:06:55 AM
#11373   I don't see how it would be possible scoot27 12/19/17 09:57:02 AM
#11372   The Nasdaq has three sets of listing requirements. simon wagstaff 12/19/17 09:40:43 AM
#11371   Simon good to see you are still around Bishop123 12/18/17 09:42:17 PM
#11370   GTBP starts process to uplist to Nasdaq Hoopasauraus 12/18/17 04:59:05 PM
#11369   News? Looks like a paid promo piece. Good simon wagstaff 12/18/17 04:18:52 PM
#11368   NEWS Oharper 12/18/17 12:45:49 PM
#11367   NEWS Oharper 12/13/17 09:36:27 AM
#11366   The latest RS seems to have fared surprisingly CashBowski 12/13/17 07:13:54 AM
#11365 news simmons420 12/06/17 08:44:50 AM
#11363   Is anyone else investing in Juno before ASH? oxis007 12/03/17 03:21:42 PM
#11362   GT Biopharma, Inc. (GTBP) to Present Data on JayP-Diddy 12/01/17 10:16:30 AM
#11361   Short at 7.00 simon wagstaff 11/30/17 09:59:43 AM
#11360   What happened to OXS-1550? I thought that simon wagstaff 11/30/17 09:28:40 AM
#11359   GTBP news out this morning TheOtcStockGuy 11/30/17 08:17:17 AM
#11358   No reason for a reverse split. Only 49 gaileo6 11/29/17 07:02:15 PM
#11357 [SMART MONEY] 11/29/17 03:38:28 PM
#11356   The lock up to 7 makes this interesting @WolfofWeedST 11/29/17 01:31:00 PM
#11355   What exactly is the potential in the pipeline? simon wagstaff 11/29/17 10:29:02 AM
#11354   I think an update would give it the Oharper 11/29/17 10:10:47 AM
#11353   I'm hoping we can get an update soon TheOtcStockGuy 11/29/17 09:54:20 AM
#11352   Looks like another reverse split before the uplisting. simon wagstaff 11/28/17 12:10:47 PM
#11351   What's up with the lawsuit? Neither of simon wagstaff 11/21/17 11:23:53 AM
#11348   I believe that also and have held on Hoopasauraus 11/17/17 10:15:49 AM
#11347   Minimum of 18 months before they submit, will simon wagstaff 11/17/17 08:06:38 AM